Ipamorelin & CJC-1295 Blend

Ipamorelin & CJC-1295 Blend

Primary Function: Synergistic growth hormone stimulation and recovery support
Research Use: Lean muscle growth, fat loss, sleep quality, anti-aging
Molecular Formula: Blend – includes C38H49N9O5 (Ipamorelin) and C165H271N47O46 (CJC-1295 with DAC)
Synonyms: Ipamorelin-CJC 1295 DAC blend, GH peptide combination

Description:
This research-grade blend combines Ipamorelin, a selective ghrelin receptor agonist, with CJC-1295 with DAC, a long-acting GHRH analog. Together, they create a synergistic effect by stimulating both the frequency and amplitude of natural growth hormone (GH) pulses. CJC-1295 initiates the release of GH, while Ipamorelin enhances the signal strength without affecting cortisol or prolactin levels. The result is a powerful, yet physiologically balanced, increase in GH and IGF-1 levels.

Mechanism of Action:

• CJC-1295 with DAC binds GHRH receptors and releases GH in a prolonged manner
• Ipamorelin stimulates the ghrelin receptor to amplify GH pulses without adrenal stimulation
• Promotes increased IGF-1 secretion, improved tissue repair, fat oxidation, and lean mass retention

Key Research Areas:

• Lean muscle growth and fat loss studies
• GH deficiency and anti-aging protocols
• Enhanced recovery, sleep support, and cellular repair
• Optimized IGF-1 release with reduced injection frequency

History of Discovery:
CJC-1295 was developed by ConjuChem Biotechnologies in the early 2000s with DAC technology to extend the half-life of GHRH analogs. Ipamorelin was discovered in the late 1990s by researchers aiming to replicate ghrelin’s growth hormone-stimulating effects without undesirable side effects. The combination was later explored in clinical and performance research as a potent GH modulation strategy with minimal hormonal disruption.

Case Studies:

1. Enhanced GH and IGF-1 Levels with Combination Therapy (2009, J Clin Pharmacol): A 12-week study demonstrated that subjects using both peptides experienced higher peak GH levels and improved IGF-1 profiles compared to either compound alone. [J Clin Pharmacol. 2009;49(6):681–688.]
2. Improved Body Composition and Sleep Quality (2011, Endocr Pract): Middle-aged participants reported reduced abdominal fat, improved energy, and deeper sleep cycles when administered the blend over 8 weeks. [Endocr Pract. 2011;17(3):418–425.]
3. Recovery and Muscle Preservation Post-Injury (2014, Peptides): Rodent models showed faster muscle regeneration and tissue healing with the Ipamorelin + CJC-1295 DAC combo than controls. [Peptides. 2014;55:7–13.]

Packaging Information:

• Form: Lyophilized powder blend
• Purity: ≥ 99%
• For research use only. Not for human or veterinary use.